CORALVILLE, Iowa, Aug. 6, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that President and CEO, Travis Mickle, Ph.D., will present at the Canaccord Genuity 34th Annual Growth Conference at the InterContinental Boston Hotel in Boston, MA.
Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's clinical, regulatory and commercial strategy for KP201, the company's lead clinical candidate for the treatment of acute moderate to moderately severe pain. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC).
Details of KemPharm's presentation are as follows: Event:Canaccord Genuity 34th Annual Growth ConferenceDate: August 13, 2014Time: 11:00 a.m. – 11:25 a.m. ETLocation:InterContinental Boston HotelAbout KemPharmKemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach. The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases. For more information on KemPharm, please visit the company's website at www.kempharm.com.For KemPharm, Inc:Media / Investor Contacts:Gordon K. "Rusty" Johnson
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
212.375.2665 / 2664
|SOURCE KemPharm, Inc.|
Copyright©2014 PR Newswire.
All rights reserved